NCT06934044

A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma

A Phase Ib, Open-Label, Single-Arm, Multicenter Trial Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Patients With Relapsed or Refractory Multiple Myeloma

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Hoffmann-La Roche · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the pharmacokinetics (PK), safety, and efficacy of cevostamab in participants with relapsed or refractory (R/R) multiple myeloma (MM).

Conditions

• Multiple Myeloma

Interventions

Type	Name	Description
DRUG	Cevostamab	Cevostamab will be administered intravenously on a 21-day cycle.
DRUG	Tocilizumab	Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.

Timeline

• Start date: 2025-05-13
• Primary completion: 2028-11-04
• Completion: 2028-11-04
• First posted: 2025-04-18
• Last updated: 2026-04-13

Locations

5 sites across 1 country: China

Regulatory

• FDA-regulated drug study